Rosuvastatin + HMG CoA inhibitor
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypercholesteremia
Conditions
Hypercholesteremia
Trial Timeline
Oct 1, 2005 → Oct 1, 2008
NCT ID
NCT00329160About Rosuvastatin + HMG CoA inhibitor
Rosuvastatin + HMG CoA inhibitor is a approved stage product being developed by Shionogi for Hypercholesteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT00329160. Target conditions include Hypercholesteremia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00329160 | Approved | Completed |
Competing Products
5 competing products in Hypercholesteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atorvastatin, Lipitor | Astellas Pharma | Approved | 85 |
| SHR-1209 + Placebo | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Rosuvastatin calcium | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin + Atorvastatin | AstraZeneca | Phase 3 | 77 |
| MK-0524A + ER Niacin + Placebo | Merck | Phase 3 | 77 |